Medical communications agency Macmillan Medical Communications (MMC), part of Macmillan Publishers Limited, UK, has announced the launch of Dissect Medicine (www.dissectmedicine.com), a collaborative medical news portal. A first of its kind, the website was launched as a joint initiative with Nature Publishing Group's medical journal division, Nature Clinical Practice.
Dissect Medicine users are required to submit news items for review with tags and keywords. These are then ranked by the user group to ensure that only the most relevant and influential articles are displayed as headline stories. Though the service is completely free, registration is required to participate.
Designed for clinicians, healthcare professionals and the general public, the website has already indexed hundreds of news items on topics such as diseases, clinical practice and biomedical research. Multiple language editions of the site are being developed in languages including Japanese, German and Spanish.
Future Medicine Ltd., part of Future Science Group, UK, has announced the launch of its latest peer-reviewed title, Nanomedicine. The journal seeks to be a valuable information source for academic, industrial and clinical researchers, pharmaceutical and biotechnology companies, regulatory authorities and others across the scientific community.
Published bimonthly, the journal addresses significant challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics. The information is delivered in concise, clear and attractive article formats, including reviews, primary research articles, technology reports, perspectives and editorials.
Topics covered will include basic research and theoretical applications, benefits of nanotechnology over traditional techniques, potential medical applications and therapeutic applications of nanotechnology advances, nanomedical tools in gene therapy, drug delivery and commercialisation, funding, economics and ethics of nanomedical technology.
Content delivery solutions provider Mainstream Data, US, has announced an agreement with global information company, Reuters, to deliver content of Reuters Health information products. A leading source of medical and healthcare news, Reuters Health services include Reuters Medical News, Reuters Health eLine, and Reuters Health Industry Briefing.
Under the deal, Mainstream Data will assume end-to-end responsibility for Reuters Health content distribution, including application hosting, server management, and support services. In addition, Mainstream will also make its suite of Medias applications and services available for future product augmentation. The company was chosen for its reputation and proven ability to deliver robust, low-cost, and customisable content delivery solutions and its unique ability to integrate Reuters Health Network platform with other Reuters platforms already running on Mainstream's networks.
Apart from e-mail and FTP 'pull' delivery, Mainstream's content distribution platform includes MediasFTP 'push' delivery, MediasNet for immediate streaming of Reuters content over the Internet, satellite delivery, and the Medias Server, an edge server platform for capture, manipulation, and display of compelling content.
Publisher McGraw-Hill Professional, part of McGraw-Hill Companies, US, has announced the addition of video news from ScienCentral, Inc., to AccessScience, its online encyclopaedia of science and technology. ScienCentral produces science and technology content for television, video and the web.
Each ScienCentral video will bring live a scientific story on AccessScience in one-and-a-half -minute segments, which are designed for general viewers. The videos will cover areas such as technology, physical sciences and life sciences. Apart from providing users with current news in scientific findings and research, the videos will also allow them to view animations as well as interviews with scientists.
ScienCentral's scientific advisory board ensures the accuracy of the content, ranging from cheaper DNA testing to the effects of genetics on exercise and "freezing" light for use in quantum computers. Updated several times a month on the AccessScience homepage, the ScienCentral videos will also be available in the Headline News archives.
Online biomedical information provider BioWizard, LLC, US, has announced the launch of PubMed Wizard, an online resource enabling the open-access review of scientific and medical literature. Scientists can now expect to freely rank and discuss, in real-time, any of the over 16 million published articles in the PubMed database.
The PubMed Wizard converts current static literature searches into an active and interconnected resource for scientists. The resource can be used by authors and researchers to post comments, share ideas and ask questions on a live archive of all published literature. It offers everyone, from top researchers to undergraduate students, the opportunity to provide instant feedback on a number of new ideas.
The BioWizard portal, with its PubMed Wizard search feature, seeks to place all relevant life sciences research content into a central, journal-independent and freely accessible location.
US-based New England Journal of Medicine has reportedly retracted a key portion of a paper it had published on the 2004 clinical trial that caused Merck to stop selling its arthritis drug, Vioxx. In a correction posted online, the journal has said that the paper's summary should no longer claim that the drug leads to heart damage only when used for over 18 months. That claim, published as one of the 2004 article's conclusions, has been at the core of Merck's defence against lawsuits filed by patients who claim that Vioxx, the brand name for the drug rofecoxib, resulted in their heart attacks and strokes.
Last month, Merck acknowledged that it had earlier misreported the results of a vital statistical test the company had said proved its 18-month theory. In fact, the test does not prove that theory, the company acknowledged.
While the journal has removed the 18-month claim from the abstract, it stays in the results section of the paper. In a separate article that the journal also published online, Stephen W. Lagakos, a statistician from Harvard who consults for the journal, also disputed Merck's claim that the drug's dangers were not evident among patients who took it for less than 18 months.
Content aggregator Dialog, part of Thomson Corporation, US, has announced that Bonnie Snow, Dialog Director of Pharmaceutical Market Applications, has received the 2006 Distinguished Member Award from the Special Libraries Association's (SLA) Pharmaceutical and Health Technology Division (P&HT). Snow was presented with the award at the recently concluded 2006 Annual Conference in Baltimore.
The Distinguished Member Award honours members for their notable and enduring contributions and service to the division and the information profession.
As a member of SLA, Snow has held several positions within the organisation, including Chair of the P&HT division (1997-1998), Professional Development Chair, P&HT division (1994-1996), and Newsletter Editorial Board member, P&HT division (1998-2000).
STM Publishers can now add their Company to the KnowledgeSpeak Directory list. You can also update our events calendar, if you are organising an event which may be of interest to the STM publishing community. Also, you can send your company press releases to be included in our news section.